Prime Medicine Bio (PRME) Market Capitalization to Book Value Ratio
The confirmed price history on the Prime Medicine, Inc. (PRME) chart demonstrates a business protected by unique patents and stringent FDA oversight. Long-term market expansion potential is based on colossal demand for the correction of hereditary pathologies, with the metric standing at 23.99. The current financial position relies on external funding and scientific achievements, as stable revenue is absent during the early research stage.
%20Capitalization%20to%20Book%20Value%20Ratio&width=1200&height=400&colorIndex=0&v=mvt4kixj.9g-7avve2o&start=20220704&end=20261029&filename=GURU_Markets_-_PRME_-_Prime-Medicine-Inc._-_Capitalization-to-Book-Value-Ratio "PRME: primemedicine.com Market Value to Book Value Ratio 04/28/2023 - 10/29/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for Prime Medicine Inc (PRME)
- share price and expert price forecast:
- market capitalization details:
- balance sheet net asset value indicators:
- debt and solvency information:
Debt to Equity Prime Medicine, Inc.|PRME - Long-Term Liabilities to Equity|Short-Term Debt to Equity Prime Medicine Corp|PRME - Aggregate Debt Obligations|Debts to Book Capitalization Prime Medicine Corp|PRME - Long-Term Debt Volume|Company Short-Term Debt Prime Medicine|Quick Ratio primemedicine.com
- earnings and market multiples details:
Summary company analytics:Prime Medicine, Inc. - PRME
This ratio compares the current market value of Prime Medicine, Inc. (PRME) to its net assets, reflecting a premium or discount to the book value of capital. High investor confidence in the scientific foundation and DNA rights protection strategy is evident in the market cap to book value ratio, confirming that the market values the company's intellectual potential significantly higher than its tangible assets.
Competitors of Prime Medicine, Inc. (PRME)
TEM: Market Capitalization to Book Value Ratio|Market-to-Book Ratio qiagen.com (QGEN)|IONS (Ionis) - Market Capitalization to Book Value Ratio|Capitalization to Book Value Ratio RGEN (Repligen Corp)|Market Value to Book Value Ratio Avidity (RNA)|CRISPR - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio WGS (GeneDx Holdings Corp.)|Market Capitalization to Book Value Ratio ultragenyx.com RARE|BEAM - Market Value to Book Value Ratio|Market Capitalization to Net Assets SRPT|Twist Bio (TWST) - Market Value to Book Value Ratio|10x - Market Value to Book Value|NTLA (Intellia Therapeutics) - Market Capitalization to Book Value Ratio|stoketherapeutics.com (STOK) - Market Capitalization to Book Value|Market Value to Book Value Ratio BioLife Solutions (BLFS)|Market Cap to Net Assets Ratio Wave Life Sciences Ltd WVE|Market Capitalization to Book Value Ratio MAZE (Maze Tx)|Sionna Corp (SION) - Market-to-Book Ratio|TSHA: Market Cap to Net Assets Ratio|Market Value to Book Value QURE (uniqure.com)|MeiraGTx (MGTX) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio REGENXBIO Inc|SLDB (Solid Bio) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Ocugen Pharma OCGN|Market Capitalization to Book Value Ratio PACB|benitec.com - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio DSGN (Design Therapeutics, Inc.)|Market Capitalization to Book Value Rocket Pharma (RCKT)|4D Molecular Therapeutics Inc - Market Capitalization to Book Value Ratio|Lexeo Therapeutics (LXEO) - Market Cap to Net Assets Ratio|KRRO: Market Capitalization to Book Value Ratio|EDIT - Market Capitalization to Book Value|Market Value to Book Value Ratio Silence Therapeutics plc|Capitalization to Book Value Ratio PRQR (ProQR Therapeutics NV)|Market Capitalization to Book Value Ratio CDXS|SGMO - Market-to-Book Ratio|Nautilus Bio - Market Cap to Net Assets Ratio|Market Value to Book Value MGX|Precision BioSciences - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Generation Bio Co. GBIO|Boundless Bio, Inc (BOLD) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio XCUR|IMNN (Imunon Inc) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio RXi Pharmaceuticals (PHIO)|Market Cap to Net Assets Ratio MBIO (Mustang Bio, Inc.)|Market Capitalization to Book Value transcodetherapeutics.com|Market Value to Book Value Ratio Bionano Genomics BNGO|APDN (Applied DNA Corp) - Market Capitalization to Net Assets|BLUE - Market Value to Book Value Ratio|Market Value to Book Value IPA (ImmunoPrecise Antibodies)|Omega Therapeutics, Inc. (OMGA) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Singular Genomics Systems, Inc.|RGLS (Regulus Therapeutics Inc) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Syros Pharmaceuticals, Inc SYRS|Market Capitalization to Book Value Ratio TBIO|traconpharma.com - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Unity Biotechnology, Inc. UBX